Femtech startup trials platform at St Mary’s Imperial Hospital

Femtech startup Adia Health has been given the opportunity to trial its platform at St Mary’s Hospital at Imperial College London.

The platform was developed following founder and CEO Lina Chan’s experience with pregnancy loss and conception, with the trial funded by the Wellcome Trust.

In a Q&A with Digital Health Age in April, Chan said: “We are helping healthcare institutions engage people better outside of the clinic by using Adia to adopt lifestyle changes that improve their physical and emotional wellbeing.

“Our platform can also be used to deliver blood tests at a significant discount to clinics and users are already able to message with doctors – saving time and money for both women and their doctors. As our product is tech based, it is accessible on mobile and from anywhere at any time enabling healthcare providers to better help people amidst their busy lives.”

The startup has been awarded the grant to answer the question: “What interventions improve mental health for women who are trying to conceive?” where they will monitor a population of women on its platform.

The report into the study is due at the end of Summer 2019.

The aim of the research grant is to enable them to better understand which interventions are the most effective in improving mental health. In developing its product, Adia has found that good preconception health improves fertility and minimises the risk of pregnancy complications.

The platform uses home blood tests as well as evidence-based interventions to improve preconception physical health such as nutrition plans, motivational prompts and lifestyle coaching, as well as mental health techniques such as mindfulness programmes and psychoeducation.

'Femtech startup trials platform at St Mary’s Imperial Hospital' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions